Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 18/20 | 0.56 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.47 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.47 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.47 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.47 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12973601 | 0.94 | P2RX3 (0.54) | P2RX3 | |
| SCHEMBL12973581 | 0.91 | P2RX3 (0.61) | P2RX3 | |
| SCHEMBL12973583 | 0.90 | P2RX3 (0.57) | P2RX3 | |
| SCHEMBL12973584 | 0.90 | P2RX3 (0.57) | P2RX3 | |
| SCHEMBL12973582 | 0.89 | P2RX3 (0.57) | P2RX3 | |
| SCHEMBL12973590 | 0.88 | P2RX3 (0.58) | P2RX3 | |
| SCHEMBL12973591 | 0.88 | P2RX3 (0.59) | P2RX3 | |
| SCHEMBL12973588 | 0.87 | P2RX3 (0.58) | P2RX3 | |
| SCHEMBL12973575 | 0.85 | P2RX3 (0.58) | P2RX3 | |
| SCHEMBL12973574 | 0.84 | P2RX3 (0.51) | P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859545-B2 | Tetrahydronaphthyridine and tetrahydropyrido[4,3-D]pyrimidine compounds and compositions thereof useful for the treatment of inflammatory and respiratory diseases | EVOTEC AG (DE) | 2014-10-14 | — | — | US | disclosed |
| US-8859545-B2 | Tetrahydronaphthyridine and tetrahydropyrido[4,3-D]pyrimidine compounds and compositions thereof useful for the treatment of inflammatory and respiratory diseases | EVOTEC AG (DE) | 2014-10-14 | — | — | US | disclosed |
| US-20100317676-A1 | Fused heterocyclic compounds, and compositions and uses thereof | RENOVIS, INC. | 2010-12-16 | — | — | US | disclosed |
| US-20100317676-A1 | Fused heterocyclic compounds, and compositions and uses thereof | RENOVIS, INC. | 2010-12-16 | — | — | US | disclosed |
| US-7745451-B2 | 2,3-Difluoro-benzyl)-[6-(5-methyl-pyridin-2-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-yl]-amine, useful for the prevention and treatment of pain, inflammation, cognitive disorders, anxiety and depression in humans | RENOVIS, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-7745451-B2 | 2,3-Difluoro-benzyl)-[6-(5-methyl-pyridin-2-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-yl]-amine, useful for the prevention and treatment of pain, inflammation, cognitive disorders, anxiety and depression in humans | RENOVIS, INC. (US) | 2010-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317676-A1 | Fused heterocyclic compounds, and compositions and uses thereof | OPRL1, OPRK1, IL1B | P2RX3 281/4885GRIN2D 82/4885GRIN3B 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.